Cargando…
The Truncated Isoform of Somatostatin Receptor5 (sst5TMD4) Is Associated with Poorly Differentiated Thyroid Cancer
Somatostatin receptors (ssts) are expressed in thyroid cancer cells, but their biological significance is not well understood. The aim of this study was to assess ssts in well differentiated (WDTC) and poorly differentiated thyroid cancer (PDTC) by means of imaging and molecular tools and its relati...
Autores principales: | Puig-Domingo, Manel, Luque, Raúl M., Reverter, Jordi L., López-Sánchez, Laura M., Gahete, Manuel D., Culler, Michael D., Díaz-Soto, Gonzalo, Lomeña, Francisco, Squarcia, Mattia, Mate, José Luis, Mora, Mireia, Fernández-Cruz, Laureano, Vidal, Oscar, Alastrué, Antonio, Balibrea, Jose, Halperin, Irene, Mauricio, Dídac, Castaño, Justo P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897452/ https://www.ncbi.nlm.nih.gov/pubmed/24465589 http://dx.doi.org/10.1371/journal.pone.0085527 |
Ejemplares similares
-
Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors
por: Sampedro-Núñez, Miguel, et al.
Publicado: (2015) -
The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients
por: Gahete, Manuel D., et al.
Publicado: (2016) -
Somatostatin Receptor Splicing Variant sst5TMD4 Overexpression in Glioblastoma Is Associated with Poor Survival, Increased Aggressiveness Features, and Somatostatin Analogs Resistance
por: Fuentes-Fayos, Antonio C., et al.
Publicado: (2022) -
Epigenetic and post‐transcriptional regulation of somatostatin receptor subtype 5 (SST(5)) in pituitary and pancreatic neuroendocrine tumors
por: Pedraza‐Arevalo, Sergio, et al.
Publicado: (2021) -
Selective Somatostatin 5 (SST5) and Somatostatin 2 (SST2) Nonpeptide Agonists Potently Suppress Glucose- and Tolbutamide-Stimulated Dynamic Insulin Secretion From Isolated Human Islets
por: Rico, Elizabeth, et al.
Publicado: (2021)